Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 1998

View Archived Issues

Estrogen: a potential agent for prevention of dementia?

COX-1 inhibition is more effective than COX-2 inhibition in a chronic inflammation model

Company Profile: Sinogen

Dusa: year-end 1997 highlights

Potent inhibitors of IL-1beta and TNF-alpha production prepared at Nisshin Flour Milling

Abbott describes novel lead structure for selective COX-2 inhibitors

AHP reports novel neuroprotectants

Company Profile: SuperGen

U.S. university scientists report novel muscarinic agonists

BB-10010 has myelosuppressive and progenitor cell-mobilizing effects in humans

LXR files IND for CP-Cardiosol

Analysis of statin results confirms beneficial clinical effects of lipid lowering on mortality

Phase II ImmTher trial begins in pediatric cancer patients

FDA clears free PSA blood test

LifeCell will be awarded U.S. patent for blood cell preservation technology

Mechanism of chemopreventive activity of resveratrol identified

GABA-A receptor ligands under evaluation at Neurogen

Ixion succeeds in lowering urinary oxalate levels with IxC1-62/47

Creative BioMolecules: year-end 1997 highlights

Fuisz closes acquisition of Rentschler

SmithKline Beecham and Ligand begin leptin-obesity collaboration

Spongiform encephalopathies advisory committee meeting scheduled

Collagenex amends NDA for Periostat

Roche benzodiazepines go head-to-head with midazolam

CytRx begins patient enrollment for Flocor phase III trial

Combivir approved in E.U.

Novel enzyme inhibitors discovered at California institute

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...